The rapid advancement of cell and gene therapies (CGTs) offers transformative potential for treating a myriad of diseases, including various cancers and genetic disorders. However, the journey from conceptualization to clinical application is fraught with challenges, particularly in the realms of Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practice (GMP) compliance. Central to these challenges is the sourcing, qualification, and management of raw materials, which are pivotal in ensuring the safety, efficacy, and consistency of CGT products.
In the context of CGT, raw materials encompass substances used during the manufacturing process that are not intended to be part of the final therapeutic product. These include culture media, growth factors, plasmids, and viral vectors essential for cell cultivation and genetic modification. In addition to these, plasmid and viral banks and Master Cell Banks (MCB) serve as foundational raw materials.
Ideal starting materials should be homogeneous, thoroughly characterized, free from adventitious agents and unwanted impurities, and consistently available for production. The quality and consistency of these materials directly influence the final product’s attributes, making their rigorous selection and management paramount.
Culture media and growth factors are critical raw materials in CGT manufacturing, as they directly impact cell growth, viability, and therapeutic efficacy. Ensuring the quality, safety, and consistency of these materials requires careful evaluation and adherence to regulatory standards.
Key Considerations:
The biological origin of culture media components, especially those derived from human or animal sources, poses inherent risks. Factors to evaluate include:
The grade of culture media and growth factors should align with the stage of development. Research-grade materials may be sufficient for early preclinical studies, but GMP-grade materials are required for clinical trials and commercialization. Regular evaluation of material specifications ensures compliance with pharmacopeial and regulatory standards.
Biological raw materials pose unique challenges due to their inherent variability and contamination risks. Comprehensive testing is necessary to ensure these materials meet regulatory requirements:
In CGT, plasmid banks, viral banks, and master cell banks are critical to ensuring product consistency, safety, and efficacy throughout the manufacturing process. These banks serve as standardized starting materials, providing a reliable foundation for large-scale production.
Establishing well-characterized cell banks is essential, particularly in the production of plasmid DNA and lentiviral vectors, as it reduces variability and enhances the reproducibility of the final therapeutic product.
| Plasmid Bank | Viral Bank | Cell Bank | |
| Definitions | A repository of plasmids used to produce viral vectors or directly modify cells through gene transfer. | A repository of viral vectors used to deliver genetic material into target cells. | A repository of a clonal cell line |
| Examples | Transgene Plasmid: Contains the therapeutic gene (e.g., a chimeric antigen receptor (CAR) for CAR-T therapies). Helper Plasmids: Provide structural proteins for viral vector packaging (e.g., gag, pol, and env genes in lentiviral vector production). CRISPR Plasmids: Deliver gene-editing tools (e.g., Cas9 and guide RNA). | Lentiviral Vector Bank: Used in CAR-T cell therapy to deliver the CAR gene. Adeno-Associated Virus (AAV) Bank: Used in gene replacement therapies (e.g., for hemophilia or spinal muscular atrophy). Retroviral Vector Bank: Used for stable gene integration in T cell receptor (TCR) therapies. | HEK293 Cell Bank: Used for viral vector production (e.g., lentiviral and AAV vectors). T Cell Bank: Engineered patient- or donor-derived T cells for cell therapies (e.g., TCR-T or CAR-T). CHO Cell Bank: Used in monoclonal antibody or protein-based therapeutic production. |
| Regulatory Considerations | Source and Construction: Document the plasmid’s origin, cloning strategy, and modifications. Characterization: Confirm identity, sequence integrity, and stability using techniques like restriction mapping and sequencing. Quality Control: Conduct tests for purity (e.g., residual host-cell DNA, endotoxin levels) and identity. Storage and Stability: Demonstrate long-term plasmid stability under GMP-compliant conditions. | Vector Characterization: Validate genetic integrity and vector copy number. Safety Testing: Conduct replication-competent virus (RCV) testing, sterility, and adventitious agent testing. Quality Control: Ensure consistent vector titer, purity, and potency. Storage and Stability: Demonstrate functional stability during long-term cryostorage. | Cell Line History: Document the origin, genetic modifications, and propagation methods. Characterization and Identity: Verify chromosomal stability, cell surface markers, and genetic integrity. Safety Testing: Conduct sterility, mycoplasma, and adventitious virus testing. Quality Control: Validate cell viability, identity, and performance. Storage and Stability: Demonstrate cryopreserved cell stability and long-term monitoring. |
The partner should have a proven track record with the specific cell lines and plasmids relevant to your therapy, ensuring they can meet the unique requirements of your production process.
Ensure the partner operates under cGMP conditions and has a comprehensive quality management system to meet all regulatory standards.
The partner should offer extensive testing services, including genetic stability, sterility, and contaminant screening, to fully characterize the plasmid/viral/cell banks.
Assess whether the partner can accommodate current production needs and future scale-up requirements, providing flexibility as your therapy progresses through clinical phases.
Consider the partner’s ability to manage logistics, including cryogenic storage and global distribution, to maintain the integrity of cell banks throughout the supply chain.
Effective communication and a collaborative approach are essential for aligning the partner’s services with your project’s specific needs and timelines.
Plasmid DNA serves as a foundational raw material in many gene therapies, acting as a template for viral vector production or direct gene delivery. Ensuring the quality of plasmid DNA is crucial, as impurities or inconsistencies can compromise therapeutic efficacy and patient safety.
Challenges:
Mitigation Strategies:
Initiating raw material qualification early in the development process is crucial for identifying and mitigating potential risks before they affect product quality. This proactive approach involves:
Early qualification not only prevents downstream disruptions but also accelerates regulatory submissions by ensuring that all materials meet the necessary standards from the outset.
Raw Material Qualification & Certification from Suppliers
The qualification and certification of raw materials—typically sourced from suppliers—are critical for ensuring the quality, safety, and regulatory compliance of CGT manufacturing.
Regulatory bodies, including the U.S. FDA, require comprehensive documentation and robust quality assurance processes to verify the integrity of materials used in therapeutic development.
While the ultimate responsibility for raw material quality lies with the end user, early material qualification and close collaboration with suppliers are essential to meet regulatory expectations and maintain product integrity.
Ensuring Raw Material Quality through Certificate of Analysis (COA) Acceptance and Independent Testing
When sourcing raw materials, end users may accept the supplier’s Certificate of Analysis (COA) if it meets specific criteria:
If the raw material is designated for research use or intended for incorporation into clinical or commercial products, additional quality control (QC) testing may be required. This testing can include:
Supplier Collaboration and Auditing
Effective collaboration with suppliers is essential for maintaining the quality and traceability of raw materials. This involves:
By fostering transparent and proactive relationships with suppliers, end users can address quality concerns promptly, mitigate supply chain risks, and ensure continuous compliance with evolving regulatory frameworks.
Documentation and Traceability for Regulatory Compliance
Maintaining comprehensive documentation is essential for supporting regulatory submissions and facilitating effective risk assessment. These documents also establish traceability throughout the manufacturing process, ensuring raw materials consistently meet quality and safety standards.
Key records include:
Accessing DMF Information:
| DMF Categories | Scope of DMF | Examples for CGT Manufacturing |
| Type I | Manufacturing Site, Facilities, Operating Procedures, and Personnel | Description of a cleanroom environment used for cell processing, including environmental monitoring procedures. |
| Type II | Drug Substances (DS), intermediates, and related materials used in their preparation; or Drug Product (DP) | Manufacturing process and characterization of viral vectors (e.g., lentivirus or adeno-associated virus) used to deliver genetic material. |
| Type III | Packaging materials | Cryogenic vials and bags used for storage and transport of CGT products. |
| Type IV | Excipients and colorant, flavor, essence, other materials used in drug production | Cryoprotectants such as dimethyl sulfoxide (DMSO) used to preserve cell viability during freezing. |
| Type V | FDA-Accepted reference information​​ and novel materials or proprietary processes not covered by other DMF categories. | Proprietary assays for measuring T cell potency and functional characterization of the final cell product. |
An Investigational New Drug (IND) application is a request submitted to the U.S. FDA to obtain authorization to administer an investigational drug to humans. This application is required before initiating clinical trials and must demonstrate that the drug is safe for human administration and that the trial design is scientifically sound.
The IND is structured according to the Common Technical Document (CTD) format, which standardizes the presentation of data across different regions. The primary sections of the IND include:
In CGT manufacturing, accurate documentation of raw materials is critical for regulatory compliance. Raw material-related documents are included in Module 3 to ensure the FDA has a comprehensive understanding of the materials, processes, and controls involved.
Here’s where each document typically fits:
| Document | IND Section |
| Letter of Authorization (LOA) to reference a Drug Master File (DMF) | Module 1 (Administrative Information) |
| Certificate of Analysis (COA) | 3.2.S (Drug Substance) or 3.2.P (Drug Product) |
| Certificate of Compliance (CoC) | 3.2.S, 3.2.P, or 3.2.R (depending on material type) |
| Material Safety Data Sheet (MSDS) | 3.2.P (Drug Product) or 3.2.R (Regional Information) |
In cell and gene therapy, raw and starting materials play a critical role in determining product quality and patient safety. Phase-appropriate GMP implementation is essential to manage the transition from research-grade to GMP-grade materials as the product advances through clinical development and toward commercialization. While research-grade materials may be suitable during preclinical development, GMP-grade materials are required for clinical trials and commercial production to meet regulatory standards. This phased approach balances the need for quality with developmental flexibility, allowing early-stage research to progress while preparing for stringent quality control in later stages.
Raw and starting materials for cell and gene therapies encompass a wide range of biological and chemical components used during manufacturing. Examples include:
Phase-Appropriate Quality Considerations
Compendial standards refer to methods and specifications outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP) and European Pharmacopoeia. These standards are widely recognized and provide established procedures for testing and ensuring product quality.
It is desirable for analytical methods for testing the quality of raw material, to follow compendial or validated non-compendial standards. The necessity for full validation depends on the development phase (preclinical, early/late-stage clinical, or commercial). In early phases, the focus is on ensuring safety and basic quality attributes, while later stages require more comprehensive characterization and compliance with GMP guidelines.
Collaborations between industry stakeholders and regulatory bodies have facilitated the development of intermediate quality materials, such as plasmid DNA, that bridge the gap between research-grade and full GMP compliance. These materials reduce costs and accelerate timelines while maintaining appropriate safety and efficacy profiles, providing flexibility during the transition to full GMP standards as products advance toward commercialization.
Implementing a risk-based framework, as outlined in USP <1043>, aids in prioritizing resources and efforts toward materials that pose the highest risk to product quality. This approach ensures that critical materials receive the most stringent controls.
Following guidelines such as USP <1043> and FDA’s “Guidance for Industry: Q9(R1) Quality Risk Management,” manufacturers can prioritize resources and controls toward materials that pose the highest risk to product integrity. This ensures that critical materials undergo the most stringent testing and management processes, thereby mitigating potential risks to the final product.
One of the significant risks in CGT manufacturing arises from the use of human- and animal-derived materials. These materials may introduce infectious agents or adventitious contaminants, which could compromise product safety and efficacy. The potential for transmission of infectious diseases, especially from animal and human sources, is a known risk that needs careful evaluation through risk assessments. Such assessments should identify potential hazards and evaluate the associated risks based on factors
As part of risk management, the FDA recommends conducting process qualification or viral clearance validation studies to evaluate the risk of introducing adventitious agents. The manufacturing process should be designed to minimize such risks, incorporating strategies like rigorous testing of raw materials and implementing control measures at each critical step.
For human- and animal-derived materials, specific risk assessments should be provided in regulatory submissions (e.g., CTD section 3.2.A.2), ensuring that material specifications and supplier sources are clearly defined.
Any changes in material suppliers should also be carefully evaluated, as different suppliers may introduce variations in raw material characteristics, which can significantly impact the safety and quality of the final CGT product.
Another important consideration is the potential presence of feeder or bystander cells and cell-derived particles in the final product. These impurities, often used during the culture of CGT products, may carry risks such as the transmission of adventitious agents. To mitigate this risk, feeder and bystander cells should be sourced from eligible donors in accordance with regulatory guidelines (21 CFR part 1271, subpart C), and subject to thorough testing for sterility, mycoplasma, and relevant human adventitious agents. The scope of testing could vary based on the banking and expansion strategy. In cases where testing is limited, manufacturers must demonstrate that the final product is free from contaminants, including species-specific viruses, to ensure safety.
It is recommend engaging with the FDA’s Office of Therapeutic Products (OTP) in CBER early in the development process, before submitting an IND, through a pre-IND or INTERACT meeting request. These meetings should address specific concerns about the safety and quality of raw materials. Any changes to materials in products under an IND or biologics license application (BLA) should be reported through the appropriate amendments or supplements, ensuring ongoing compliance and regulatory alignment.
Successful development and commercialization of CGTs depend on the quality and consistency of raw materials used in manufacturing. Proper sourcing, qualification, and management of materials like culture media, growth factors, and plasmid/viral banks are essential for product safety, efficacy, and regulatory compliance. Manufacturers must adopt proactive strategies, including robust qualification processes, supplier collaboration, and documentation, to mitigate risks. Phase-appropriate GMP ensures a smooth transition from development to production, meeting the demands of patient safety and product quality, ultimately advancing CGTs from innovation to real-world solutions.
References:
Connect With Our Technical Specialist.
Request For A Quotaiton
DON’T MISS OUR.
FOLLOW US ON SOCIAL MEDIA!
The rapid growth of translational applications for mesenchymal stem cells (MSCs) has heightened the need for efficient, scalable production systems. Central to this effort is
China’s Dual-Track Regulatory System: Shaping the Future of Cell Therapy Research and Commercialization Cell therapy has rapidly advanced, driven by the FDA’s 2017 approval of
Gene therapy holds immense promise for managing or even curing diseases once considered untreatable. Conditions like certain cancers, β-thalassemia, and retinal dystrophy benefit from this
Contact our Customer Care, Sales & Scientific Assistance
Consult and asked questions about our products & services
Documentation of Technical & Safety Data Sheet, Guides and more..